Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Apollomics Inc. Class A Ordinary Shares

Healthcare US APLM

14.07USD
-0.13(0.92%)

Last update at 2026-06-03T14:29:00Z

Day Range

13.7314.45
LowHigh

52 Week Range

3.6640.02
LowHigh

Fundamentals

  • Previous Close 14.20
  • Market Cap29.05M
  • Volume7437
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-26.35900M
  • Revenue TTM6.93M
  • Revenue Per Share TTM6.29
  • Gross Profit TTM 6.93M
  • Diluted EPS TTM-26.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -53.59900M -172.59100M -240.81000M -94.79600M -74.90500M
Minority interest - - - - -
Net income -53.85800M -172.60100M -240.81100M -94.79700M -74.82000M
Selling general administrative 17.77M 20.64M 9.95M 15.29M 11.04M
Selling and marketing expenses - - - - -
Gross profit 0.20M 0.82M - - -
Reconciled depreciation 0.36M 0.67M 0.78M 0.68M 0.61M
Ebit -41.12700M -53.54900M -240.21100M -91.75100M -74.08500M
Ebitda -41.05500M -53.44600M -239.43600M -91.07000M -73.47600M
Depreciation and amortization 0.07M 0.10M 0.78M 0.68M 0.61M
Non operating income net other - - - - -
Operating income -42.13600M -54.01300M -240.21100M -91.75100M -74.08500M
Other operating expenses 42.33M 54.83M 44.39M 50.27M 40.75M
Interest expense 0.18M 0.15M 0.09M 0.08M 0.07M
Tax provision 0.26M 0.01000M 0.00100M 0.00100M -0.08500M
Interest income 0.48M 0.75M 0.43M 0.47M 0.33M
Net interest income 0.30M 0.60M 0.34M 0.38M -3.52400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.26M 0.01000M 0.00100M 0.00100M -0.08500M
Total revenue 0.20M 0.82M 0.00000M 0.00000M 0.00000M
Total operating expenses 42.33M 54.83M 44.39M 50.27M 40.75M
Cost of revenue 0.36M 0.69M - - -
Total other income expense net -11.46300M -118.57800M -196.76000M -44.90800M -30.62700M
Discontinued operations - - - - -
Net income from continuing ops -53.85800M -172.60100M -240.81100M -94.79700M -74.82000M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 13.10M 55.39M 76.47M 123.44M 169.94M
Intangible assets 1.74M 14.76M 14.78M 14.80M 10.32M
Earning assets - - - - -
Other current assets 0.37M - - - -
Total liab 8.23M 14.15M 524.60M 336.30M 297.87M
Total stockholder equity 4.86M 41.23M -448.12000M -212.86200M -127.93300M
Deferred long term liab - - - - -
Other current liab 7.17M 9.16M 11.74M 13.05M 11.57M
Common stock 0.01M 0.00900M 0.04M 0.04M 0.04M
Capital stock 0.01M 0.00900M 0.04M 0.04M 0.04M
Retained earnings -700.82300M -646.96500M -474.60000M -235.43500M -141.54300M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 9.77M 32.06M 32.67M 46.74M 130.65M
Cash and equivalents - - - - -
Total current liabilities 7.40M 13.56M 12.36M 13.56M 12.08M
Current deferred revenue - - - - -
Net debt -8.80000M -27.39500M -31.68400M -45.70400M -129.13400M
Short term debt 0.23M 4.39M 0.61M 0.51M 0.51M
Short long term debt - 4.24M - - -
Short long term debt total 0.97M 4.66M 0.99M 1.04M 1.51M
Other stockholder equity 702.24M 684.75M 23.04M 10.24M 8.50M
Property plant equipment - - - - -
Total current assets 10.27M 39.92M 55.79M 99.37M 157.66M
Long term investments - 0.00000M 4.31M 7.84M 0.00000M
Net tangible assets - - - - -
Short term investments 0.01M 5.76M 21.94M 47.74M 23.74M
Net receivables 0.13M 0.47M 0.55M 0.51M 0.41M
Long term debt - - - - -
Inventory - - - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 3.44M 3.44M 3.40M 12.29M 5.08M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.07M 0.12M 0.12M 0.11M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 2.83M 15.46M 20.68M 24.07M 12.28M
Capital lease obligations 0.97M 0.42M 0.99M 1.04M 1.51M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 5.98M 21.36M 29.05M -38.95000M 2.33M
Change to liabilities - - - - -
Total cashflows from investing activities 5.98M 21.36M - - -
Net borrowings 0.66M 24.04M - - -
Total cash from financing activities 0.47M 21.23M -0.29400M -1.64300M 125.51M
Change to operating activities - - - - -
Net income -53.85800M -172.60100M -240.81000M -94.79600M -74.90500M
Change in cash -22.29000M -0.61900M -14.06500M -83.90500M 92.16M
Begin period cash flow 32.06M 32.67M 46.74M 130.65M 38.49M
End period cash flow 9.77M 32.06M 32.67M 46.74M 130.65M
Total cash from operating activities -28.74300M -43.20900M -42.82400M -43.31200M -35.68100M
Issuance of capital stock - - 0.39M 0.14M 6.03M
Depreciation 0.36M 0.67M 0.78M 0.68M 0.61M
Other cashflows from investing activities 6.01M 21.37M - - -
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities -4.41100M 4.11M -0.09300M -1.25600M 119.96M
Change to netincome - - - - -
Capital expenditures 0.02M 0.00600M 0.37M 7.55M 10.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.61M -0.93200M 6.49M 2.64M 3.06M
Stock based compensation 10.93M 12.69M 3.58M 8.12M 4.51M
Other non cash items 12.22M 116.97M 187.14M 40.04M 31.04M
Free cash flow -28.76700M -43.21500M -43.19100M -50.86200M -45.82500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
APLM
Apollomics Inc. Class A Ordinary Shares		 -0.13 0.92% 14.07 - - 4.19 8.15 3.35 -0.0984
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.38 0.89% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its immuno-oncology product candidates comprise APL-501, APL-502, and APL-801. The company was founded in 2015 and is based in Foster City, California.

Apollomics Inc. Class A Ordinary Shares

989 East Hillsdale Blvd., Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Dr. Guo-Liang Yu Ph.D. Co-Founder, CEO & Executive Chairman 1963
Dr. Sanjeev Redkar MBA, Ph.D. Co-Founder, President & Executive Director 1969
Dr. Matthew James Plunkett Ph.D. Chief Financial Officer 1972
Dr. Kin-Hung Yu M.D. Chief Medical Officer 1962
Dr. Chinglin Lai Ph.D. Senior Vice President of Biostatistics & Data Management NA
Mr. Hung-Wen Chen CEO & Chairman of the Board 1962
Mr. K. H. Lin C.A.I.A., M.B.A. Chief Financial Officer 1970
Mr. Yi-Kuei Chen Director & COO 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions